{"success":true,"data":{"pressRelease":{"id":"63587","rtpr_id":"nGNE7JBw5K","ticker":"ENLV","exchange":"NASDAQ","all_tickers":["ENLV","1BTG"],"title":"Enlivex Announces Issuance of Australian Patent Covering the Use of Allocetra™  in Patients with Osteoarthritis","author":"Globe Newswire","published_at":"2026-06-15T12:00:00.337Z","article_body":"Nes-Ziona, Israel, June 15, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq:\nENLV) (\"Enlivex\" or the \"Company\"), a quality longevity company powered by a\nprediction markets treasury, today announced the issuance of an Australian\npatent, numbered 2020340629, titled, “THERAPEUTIC APOPTOTIC CELLS FOR\nTREATMENT OF OSTEOARTHRITIS”. The patent will provide Enlivex with added\nintellectual property protection in Australia through at least 2040 with\nclaims covering methods of using Allocetra™ to treat subjects with\nosteoarthritis. With this issuance, the Company has secured patent protection\nfor Allocetra™ in osteoarthritis in an additional major jurisdiction,\nfurther strengthening its global intellectual property position as the Phase\n2b clinical program for Allocetra™ advances.\n\nEnlivex recently reported the dosing of the first patient at a U.S. clinical\nsite in the Phase 2b clinical trial of Allocetra™ for the treatment of\npatients with moderate-to-severe age-related symptomatic primary knee\nosteoarthritis (OA). The Phase 2b follows Enlivex’s previous announcement\nregarding positive three-month and six-month topline data from the Phase 2b\nstage of ENX-CL-05-001, a multi-center, two-stage Phase I/II double-blind,\nrandomized, placebo-controlled clinical trial that evaluated Allocetra™ in\npatients with moderate-to-severe knee OA.\n\nAbout Enlivex (Nasdaq: ENLV)\n\nEnlivex is a quality longevity company powered by a prediction markets\ntreasury. The Company is advancing Allocetra™, an advanced clinical-stage\nimmunotherapy targeting inflammatory conditions associated with aging, with a\nprimary focus on age-related osteoarthritis. In addition to its clinical\nprograms, Enlivex operates a prediction markets treasury strategy built around\nthe Rain protocol, the leading decentralized prediction markets infrastructure\non Arbitrum. This dual strategy combines the development of quality longevity\ntherapeutics with exposure to the emerging prediction markets ecosystem.\n\nAbout Knee Osteoarthritis\n\nKnee osteoarthritis (KOA) is one of the most prevalent and disabling diseases\nworldwide, affecting more than 32 million Americans today and projected to\nimpact 78 million Americans by 2040. There are currently no approved disease\nmodifying therapies; treatment is largely limited to pain relief,\nintra-articular steroids, or surgery, and the burden increases sharply with\nage. By age 60, KOA affects roughly 30% of the population, and about half of\nknee OA patients are 60 years and older. This demographic is expanding with\nglobal aging trends, underscoring the need for new, durable therapies.\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements within the meaning of\nSection 27A of the Securities Act of 1933, as amended, and Section 21E of the\nSecurities Exchange Act of 1934, as amended. These forward-looking statements\nmay be identified by words such as \"expects,\" \"plans,\" \"projects,\" \"will,\"\n\"may,\" \"anticipates,\" \"believes,\" \"should,\" \"would,\" \"could,\" \"intends,\"\n\"estimates,\" \"suggests,\" \"target,\" \"has the potential to,\" \"goal,\" and other\nwords of similar meaning, including statements relating to the anticipated\nbenefits of the Company's digital asset treasury strategy; the assets to be\nheld by the Company; the expected future market, price, trading activity, and\nliquidity of the RAIN token; the impact of expanded exchange listings and\nincreased token liquidity on market participation and accessibility; the\npotential effects of digital asset liquidity on the liquidity of the Company's\nordinary shares; macroeconomic, political, and regulatory conditions\nsurrounding digital assets; the Company's plans for value creation and\nstrategic positioning; market size and growth opportunities; regulatory\nconditions; competitive position; technological and market trends; future\nfinancial condition and performance; expected clinical trial results; market\nopportunities for the results of current clinical studies and preclinical\nexperiments; and the effectiveness of, and market opportunities for,\nALLOCETRA™ programs. Each forward-looking statement contained in this press\nrelease is subject to risks and uncertainties that could cause actual results\nto differ materially from those expressed or implied by such statement.\nApplicable risks and uncertainties include, among others, the risk of failure\nto realize the anticipated benefits of the Company's digital asset treasury\nstrategy; changes in business, market, financial, political, and regulatory\nconditions; risks relating to the Company's operations and business, including\nthe highly volatile nature of the price, trading volume, and liquidity of RAIN\nand other cryptocurrencies; risks associated with digital asset exchange\nlistings, trading venues, and market infrastructure; the risk that the price\nand liquidity of the Company's ordinary shares may be correlated with the\nprice or liquidity of the digital assets it holds; risks related to increased\ncompetition in the industries in which the Company operates; risks relating to\nsignificant legal, commercial, regulatory, and technical uncertainty regarding\ndigital assets generally; risks relating to the treatment of crypto assets for\nU.S. and foreign tax purposes; and those risks and uncertainties identified in\nthe Company's filings with the Securities and Exchange Commission. The\nforward-looking statements in this press release speak only as of the date of\nthis document, and the Company undertakes no obligation to update or revise\nany of these statements, except as required by applicable law.\n\nENLIVEX CONTACT\n\nShachar Shlosberger, CFO Enlivex Ltd. shachar@enlivex.com","article_body_html":"","raw_payload":{"data":{"id":"nGNE7JBw5K","title":"Enlivex Announces Issuance of Australian Patent Covering the Use of Allocetra™  in Patients with Osteoarthritis","author":"Globe Newswire","ticker":"ENLV","created":"2026-06-15T12:00:00.337Z","tickers":["ENLV","1BTG"],"exchange":"NASDAQ","article_body":"Nes-Ziona, Israel, June 15, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq:\nENLV) (\"Enlivex\" or the \"Company\"), a quality longevity company powered by a\nprediction markets treasury, today announced the issuance of an Australian\npatent, numbered 2020340629, titled, “THERAPEUTIC APOPTOTIC CELLS FOR\nTREATMENT OF OSTEOARTHRITIS”. The patent will provide Enlivex with added\nintellectual property protection in Australia through at least 2040 with\nclaims covering methods of using Allocetra™ to treat subjects with\nosteoarthritis. With this issuance, the Company has secured patent protection\nfor Allocetra™ in osteoarthritis in an additional major jurisdiction,\nfurther strengthening its global intellectual property position as the Phase\n2b clinical program for Allocetra™ advances.\n\nEnlivex recently reported the dosing of the first patient at a U.S. clinical\nsite in the Phase 2b clinical trial of Allocetra™ for the treatment of\npatients with moderate-to-severe age-related symptomatic primary knee\nosteoarthritis (OA). The Phase 2b follows Enlivex’s previous announcement\nregarding positive three-month and six-month topline data from the Phase 2b\nstage of ENX-CL-05-001, a multi-center, two-stage Phase I/II double-blind,\nrandomized, placebo-controlled clinical trial that evaluated Allocetra™ in\npatients with moderate-to-severe knee OA.\n\nAbout Enlivex (Nasdaq: ENLV)\n\nEnlivex is a quality longevity company powered by a prediction markets\ntreasury. The Company is advancing Allocetra™, an advanced clinical-stage\nimmunotherapy targeting inflammatory conditions associated with aging, with a\nprimary focus on age-related osteoarthritis. In addition to its clinical\nprograms, Enlivex operates a prediction markets treasury strategy built around\nthe Rain protocol, the leading decentralized prediction markets infrastructure\non Arbitrum. This dual strategy combines the development of quality longevity\ntherapeutics with exposure to the emerging prediction markets ecosystem.\n\nAbout Knee Osteoarthritis\n\nKnee osteoarthritis (KOA) is one of the most prevalent and disabling diseases\nworldwide, affecting more than 32 million Americans today and projected to\nimpact 78 million Americans by 2040. There are currently no approved disease\nmodifying therapies; treatment is largely limited to pain relief,\nintra-articular steroids, or surgery, and the burden increases sharply with\nage. By age 60, KOA affects roughly 30% of the population, and about half of\nknee OA patients are 60 years and older. This demographic is expanding with\nglobal aging trends, underscoring the need for new, durable therapies.\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements within the meaning of\nSection 27A of the Securities Act of 1933, as amended, and Section 21E of the\nSecurities Exchange Act of 1934, as amended. These forward-looking statements\nmay be identified by words such as \"expects,\" \"plans,\" \"projects,\" \"will,\"\n\"may,\" \"anticipates,\" \"believes,\" \"should,\" \"would,\" \"could,\" \"intends,\"\n\"estimates,\" \"suggests,\" \"target,\" \"has the potential to,\" \"goal,\" and other\nwords of similar meaning, including statements relating to the anticipated\nbenefits of the Company's digital asset treasury strategy; the assets to be\nheld by the Company; the expected future market, price, trading activity, and\nliquidity of the RAIN token; the impact of expanded exchange listings and\nincreased token liquidity on market participation and accessibility; the\npotential effects of digital asset liquidity on the liquidity of the Company's\nordinary shares; macroeconomic, political, and regulatory conditions\nsurrounding digital assets; the Company's plans for value creation and\nstrategic positioning; market size and growth opportunities; regulatory\nconditions; competitive position; technological and market trends; future\nfinancial condition and performance; expected clinical trial results; market\nopportunities for the results of current clinical studies and preclinical\nexperiments; and the effectiveness of, and market opportunities for,\nALLOCETRA™ programs. Each forward-looking statement contained in this press\nrelease is subject to risks and uncertainties that could cause actual results\nto differ materially from those expressed or implied by such statement.\nApplicable risks and uncertainties include, among others, the risk of failure\nto realize the anticipated benefits of the Company's digital asset treasury\nstrategy; changes in business, market, financial, political, and regulatory\nconditions; risks relating to the Company's operations and business, including\nthe highly volatile nature of the price, trading volume, and liquidity of RAIN\nand other cryptocurrencies; risks associated with digital asset exchange\nlistings, trading venues, and market infrastructure; the risk that the price\nand liquidity of the Company's ordinary shares may be correlated with the\nprice or liquidity of the digital assets it holds; risks related to increased\ncompetition in the industries in which the Company operates; risks relating to\nsignificant legal, commercial, regulatory, and technical uncertainty regarding\ndigital assets generally; risks relating to the treatment of crypto assets for\nU.S. and foreign tax purposes; and those risks and uncertainties identified in\nthe Company's filings with the Securities and Exchange Commission. The\nforward-looking statements in this press release speak only as of the date of\nthis document, and the Company undertakes no obligation to update or revise\nany of these statements, except as required by applicable law.\n\nENLIVEX CONTACT\n\nShachar Shlosberger, CFO Enlivex Ltd. shachar@enlivex.com"},"type":"article","timestamp":"2026-06-15T12:00:00.875689607Z","server_sent_at_ms":1781524800875},"received_at":"2026-06-15T12:00:00.990Z","source_url":null},"analysis":{"id":"53010","press_release_id":"63587","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["Company operates a 'prediction markets treasury' strategy involving crypto assets (Rain protocol), introducing high volatility and regulatory risk unrelated to core biotech operations.","Forward-looking statements highlight risks related to digital asset liquidity, price volatility, and regulatory uncertainty for crypto holdings."],"eventType":"regulatory","narrative":"Enlivex announced the issuance of Australian patent 2020340629, covering the use of its lead asset Allocetra for treating osteoarthritis. The patent provides intellectual property protection in Australia through at least 2040, strengthening the company's global IP position.\n\nThe release coincides with operational progress in the Phase 2b clinical trial for Allocetra in knee osteoarthritis, noting that the first patient has been dosed at a U.S. clinical site. This follows previously reported positive topline data from earlier stages of the trial.\n\nEnlivex continues to operate a dual strategy combining clinical-stage immunotherapy development with a prediction markets treasury built on the Rain protocol, exposing the company to both biotech and crypto ecosystem dynamics.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"IP moat expands for Allocetra with new Australian patent; Phase 2b trial advances with first US patient dosed."},"keyFigures":{"drugName":"Allocetra","phaseOfTrial":"Phase 2b","customDimensions":{"patent_expiry":"2040","patent_number":"2020340629","oa_patients_us_current":"32 million","oa_patients_us_projected_2040":"78 million"}},"quotedText":"The patent will provide Enlivex with added intellectual property protection in Australia through at least 2040 with claims covering methods of using Allocetra™ to treat subjects with osteoarthritis.","namedEntities":{"people":[{"name":"Shachar Shlosberger","role":"CFO"}],"products":["Allocetra","Rain protocol"],"companies":[{"name":"Enlivex Ltd.","ticker":"ENLV"}],"dollarAmounts":[]},"materialImpact":{"score":3,"reasoning":"Issuance of a key IP patent in a major jurisdiction (Australia) strengthens the commercial moat for the lead asset Allocetra. The release also confirms progress in the Phase 2b clinical trial (first patient dosed in US), which is a positive operational milestone, though not a binary readout yet."},"tickerRelevance":{"others":[],"primary":"ENLV"},"globalImportance":25,"audienceRelevance":30,"eventTypeSecondary":["clinical_trial"],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"ip_milestone_clinical_progress","sectorWeight":"biotech","cryptoExposure":"high_risk_factor","householdBrandBoost":0,"retailFavoriteBoost":5}},"event_type":"regulatory","event_type_secondary":["clinical_trial"],"sentiment":"bullish","material_impact_score":3,"narrative":"Enlivex announced the issuance of Australian patent 2020340629, covering the use of its lead asset Allocetra for treating osteoarthritis. The patent provides intellectual property protection in Australia through at least 2040, strengthening the company's global IP position.\n\nThe release coincides with operational progress in the Phase 2b clinical trial for Allocetra in knee osteoarthritis, noting that the first patient has been dosed at a U.S. clinical site. This follows previously reported positive topline data from earlier stages of the trial.\n\nEnlivex continues to operate a dual strategy combining clinical-stage immunotherapy development with a prediction markets treasury built on the Rain protocol, exposing the company to both biotech and crypto ecosystem dynamics.","key_figures":{"drugName":"Allocetra","phaseOfTrial":"Phase 2b","customDimensions":{"patent_expiry":"2040","patent_number":"2020340629","oa_patients_us_current":"32 million","oa_patients_us_projected_2040":"78 million"}},"named_entities":{"people":[{"name":"Shachar Shlosberger","role":"CFO"}],"products":["Allocetra","Rain protocol"],"companies":[{"name":"Enlivex Ltd.","ticker":"ENLV"}],"dollarAmounts":[]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-15T12:03:19.895Z","global_importance":25,"audience_relevance":30,"importance_components":{"tickerTier":"small-cap","eventGravity":"ip_milestone_clinical_progress","sectorWeight":"biotech","cryptoExposure":"high_risk_factor","householdBrandBoost":0,"retailFavoriteBoost":5}},"durationMs":55185,"modelName":"george-droid-qwen-72b"}}